■肠道菌群及其代谢产物对脓毒症患者肠道损伤的保护作用尚不清楚。
■从被分类为脓毒症和非脓毒症组的患者获得粪便样品,用于通过16SrRNA测序和非靶向代谢组学分析来分析微生物组成。我们评估了脓毒症患者肠道菌群对抗生素治疗小鼠肠道屏障的影响。此外,我们进行了Spearman相关分析,以检查代谢产物与脓毒症严重程度之间的关系。此外,我们进行了动物实验以验证鉴定的代谢物的功能.
■与对照组相比,败血症患者的肠道菌群多样性降低。通过粪便微生物移植实验,研究发现,来自败血症患者的肠道微生物群可以在抗生素治疗的小鼠中引起肠道损伤。微生物群的代谢组学分析揭示了缬氨酸的显著富集,亮氨酸,和异亮氨酸生物合成途径。进一步的分析显示脓毒症患者L-缬氨酸的丰度显著降低,与APACHE-II和SOFA评分呈负相关。在脓毒症小鼠实验中,发现L-缬氨酸可以减轻脓毒症引起的肠道损伤。
■肠道微生物和代谢特征的改变可影响脓毒症的严重程度。此外,L-缬氨酸对脓毒症肠损伤有保护作用。
UNASSIGNED: The protective role of gut microbiota and its metabolites against intestinal damage in sepsis patients remain unclear.
UNASSIGNED: Fecal samples were acquired from patients categorized into sepsis and non-sepsis groups for analysis of microbial composition via 16S rRNA sequencing and untargeted metabolomics analysis. We assessed the impact of gut microbiota from sepsis patients on intestinal barriers in antibiotic-treated mice. Furthermore, We conducted spearman\'s correlation analysis to examine the relationship between metabolites and the severity of sepsis. Additionally, we performed animal experiments to validate the functionality of identified metabolites.
UNASSIGNED: The diversity of intestinal flora is decreased in patients with sepsis compared to the control group. Through fecal microbiota transplantation experiments, it was discovered that the gut microbiota derived from sepsis patients could induce intestinal damage in antibiotic-treated mice. Metabolomics analysis of the microbiota revealed a significant enrichment of the
Valine, leucine, and isoleucine biosynthesis pathway. Further analysis showed a significant decrease in the abundance of L-
valine in sepsis patients, which was negatively correlated with APACHE-II and SOFA scores. In sepsis mouse experiments, it was found that L-
valine could alleviate sepsis-induced intestinal damage.
UNASSIGNED: Alterations in microbial and metabolic features in the gut can affect the severity of sepsis. Furthermore, L-
valine can protect against sepsis-induced intestinal injury.